November 2012 Br J Cardiol 2012;19:158–9
BJCardio Staff
While general recommendations regarding the intensiveness of glycaemic therapy focused in the past on a HbA1c target below 7%, the new statement emphasises that goals must be individualised, with the precise target taking into account patient’s attitude and expected treatment efforts, the risk associated with glycaemia and other adverse effects, disease duration, life expectancy, other co-morbidities, established vascular complications, and the patient’s own resources and support system. It notes, for example, some patients may feel that the weight gain associated with a particular diabetes therapy is unacceptable, whereas others may cons
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits